论文部分内容阅读
目的探讨新辅助化疗方案在乳腺癌治疗中的疗效和毒副反应。方法我院2012年6月—2013年9月收治的60例乳腺癌患者分为观察组30例,采用多西紫杉醇联合表柔比星进行化疗;对照组30例,采用环磷酰胺、表柔比星、氟尿嘧啶化疗,观察2组的疗效和毒副反应。结果观察组10例患者完全缓解,12例患者部分缓解,7例患者稳定,1例恶化,总有效率为73%;对照组10例患者完全缓解,8例患者部分缓解,8例患者稳定,4例恶化,总有效率为60%,2组比较差异有显著性(P<0.05)。结论新辅助化疗方案在乳腺癌的治疗中疗效明显,耐受良好,效果优于联合治疗乳腺癌的化疗方案。
Objective To investigate the efficacy and side effects of neoadjuvant chemotherapy in the treatment of breast cancer. Methods Sixty patients with breast cancer who were admitted to our hospital from June 2012 to September 2013 were divided into observation group (n = 30) and docetaxel combined with epirubicin for chemotherapy. The control group (n = 30) was treated with cyclophosphamide Than Star, fluorouracil chemotherapy, observed the efficacy and side effects of two groups. Results In the observation group, 10 patients were completely relieved, 12 patients were partially relieved, 7 patients were stable and 1 patient was deteriorated with a total effective rate of 73%. In the control group, 10 patients were completely relieved, 8 patients were partially relieved, 8 patients were stable, 4 cases of deterioration, the total effective rate was 60%, the difference between the two groups was significant (P <0.05). Conclusion The neoadjuvant chemotherapy regimen is effective and effective in the treatment of breast cancer, which is better than the combination regimen of breast cancer chemotherapy.